Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 10 | 2022 | 42 | 1.850 |
Why?
|
| Heart-Assist Devices | 5 | 2022 | 26 | 1.210 |
Why?
|
| Heart Defects, Congenital | 6 | 2021 | 92 | 1.040 |
Why?
|
| Heart Failure | 4 | 2022 | 234 | 0.870 |
Why?
|
| Graft Rejection | 3 | 2018 | 33 | 0.720 |
Why?
|
| Fontan Procedure | 3 | 2016 | 24 | 0.670 |
Why?
|
| Heparin | 7 | 2005 | 110 | 0.650 |
Why?
|
| Postoperative Care | 1 | 2018 | 67 | 0.600 |
Why?
|
| Glucocorticoids | 1 | 2018 | 114 | 0.590 |
Why?
|
| Disease Management | 1 | 2018 | 85 | 0.580 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 141 | 0.560 |
Why?
|
| Fibrosis | 1 | 2016 | 121 | 0.500 |
Why?
|
| Child, Preschool | 10 | 2022 | 1099 | 0.490 |
Why?
|
| Infant | 10 | 2021 | 964 | 0.470 |
Why?
|
| Child | 12 | 2022 | 2159 | 0.430 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2011 | 3 | 0.390 |
Why?
|
| Pneumocystis carinii | 1 | 2011 | 2 | 0.390 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2009 | 26 | 0.350 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2450 | 0.330 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2009 | 102 | 0.330 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2008 | 3 | 0.310 |
Why?
|
| Adolescent | 9 | 2022 | 2986 | 0.310 |
Why?
|
| Pheochromocytoma | 1 | 2008 | 9 | 0.310 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 15 | 0.310 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2008 | 26 | 0.310 |
Why?
|
| Heart Diseases | 3 | 2022 | 69 | 0.300 |
Why?
|
| Registries | 2 | 2021 | 383 | 0.290 |
Why?
|
| Male | 15 | 2021 | 13003 | 0.270 |
Why?
|
| Graft Survival | 3 | 2018 | 27 | 0.270 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 247 | 0.250 |
Why?
|
| Humans | 23 | 2022 | 27067 | 0.240 |
Why?
|
| Waiting Lists | 3 | 2012 | 9 | 0.220 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 985 | 0.220 |
Why?
|
| Female | 12 | 2021 | 14613 | 0.210 |
Why?
|
| Vitronectin | 1 | 2001 | 3 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2022 | 2278 | 0.190 |
Why?
|
| Time Factors | 4 | 2021 | 1570 | 0.180 |
Why?
|
| Infant, Newborn | 6 | 2021 | 846 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 90 | 0.170 |
Why?
|
| HLA Antigens | 2 | 2011 | 61 | 0.160 |
Why?
|
| Health Information Systems | 1 | 2018 | 1 | 0.150 |
Why?
|
| Complement Activation | 3 | 2005 | 25 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 18 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 29 | 0.150 |
Why?
|
| Clonal Anergy | 2 | 2009 | 11 | 0.150 |
Why?
|
| Iowa | 1 | 2017 | 3 | 0.150 |
Why?
|
| Pulsatile Flow | 1 | 2017 | 9 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2017 | 26 | 0.150 |
Why?
|
| Biopsy | 1 | 2018 | 201 | 0.150 |
Why?
|
| Myocardium | 1 | 2018 | 179 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2017 | 146 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 162 | 0.140 |
Why?
|
| Length of Stay | 1 | 2017 | 215 | 0.130 |
Why?
|
| Heart | 1 | 2017 | 221 | 0.130 |
Why?
|
| Prognosis | 1 | 2018 | 763 | 0.130 |
Why?
|
| Surface Plasmon Resonance | 2 | 2005 | 37 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 6 | 0.120 |
Why?
|
| Transposition of Great Vessels | 1 | 2015 | 8 | 0.120 |
Why?
|
| Antithrombin III | 1 | 1995 | 6 | 0.120 |
Why?
|
| Elapid Venoms | 2 | 1994 | 3 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2016 | 605 | 0.120 |
Why?
|
| Zymosan | 1 | 1994 | 1 | 0.110 |
Why?
|
| Age Factors | 2 | 2012 | 721 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2012 | 19 | 0.100 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1992 | 35 | 0.100 |
Why?
|
| Survival Rate | 4 | 2016 | 408 | 0.100 |
Why?
|
| Histocompatibility Testing | 2 | 2011 | 14 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2011 | 26 | 0.100 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2011 | 3 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2011 | 15 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 37 | 0.090 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2010 | 4 | 0.090 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2011 | 25 | 0.090 |
Why?
|
| Complement C3b | 1 | 1990 | 4 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 33 | 0.090 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 32 | 0.090 |
Why?
|
| Th1 Cells | 2 | 2009 | 35 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 171 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2009 | 29 | 0.080 |
Why?
|
| Young Adult | 2 | 2018 | 2624 | 0.080 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2001 | 38 | 0.080 |
Why?
|
| Animals | 8 | 2009 | 10073 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 15 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2001 | 118 | 0.070 |
Why?
|
| United States | 3 | 2021 | 2056 | 0.070 |
Why?
|
| Hemocyanins | 1 | 2006 | 7 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2006 | 33 | 0.070 |
Why?
|
| Antigens | 1 | 2006 | 66 | 0.070 |
Why?
|
| Risk Factors | 4 | 2012 | 2029 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2006 | 103 | 0.060 |
Why?
|
| Properdin | 1 | 2005 | 1 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 1995 | 239 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 264 | 0.060 |
Why?
|
| Heparitin Sulfate | 1 | 2005 | 14 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2005 | 24 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 1496 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 489 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 93 | 0.060 |
Why?
|
| Ribonucleases | 2 | 1995 | 9 | 0.060 |
Why?
|
| Blood Proteins | 2 | 1995 | 64 | 0.050 |
Why?
|
| Heart Ventricles | 2 | 2015 | 133 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2006 | 774 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2012 | 39 | 0.050 |
Why?
|
| Mice | 3 | 2009 | 4470 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 57 | 0.050 |
Why?
|
| Hospitalization | 1 | 2022 | 189 | 0.040 |
Why?
|
| Catheterization | 1 | 2000 | 50 | 0.040 |
Why?
|
| Polymers | 1 | 2001 | 114 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 2000 | 37 | 0.040 |
Why?
|
| Complement C3 | 3 | 1995 | 21 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 251 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 189 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2000 | 84 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2000 | 133 | 0.040 |
Why?
|
| Peroxidases | 2 | 1995 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 508 | 0.040 |
Why?
|
| Guinea Pigs | 2 | 1994 | 73 | 0.030 |
Why?
|
| Complement Pathway, Classical | 1 | 1995 | 2 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1995 | 7 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 1995 | 54 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1995 | 239 | 0.030 |
Why?
|
| Swine | 1 | 1995 | 220 | 0.030 |
Why?
|
| Binding Sites | 1 | 1995 | 341 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1995 | 186 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 128 | 0.030 |
Why?
|
| Polysaccharide-Lyases | 1 | 1993 | 2 | 0.030 |
Why?
|
| Carbohydrate Sequence | 1 | 1992 | 14 | 0.030 |
Why?
|
| Complement Pathway, Alternative | 1 | 1992 | 1 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1993 | 113 | 0.030 |
Why?
|
| Eosinophils | 1 | 1992 | 6 | 0.030 |
Why?
|
| Cause of Death | 1 | 2012 | 66 | 0.030 |
Why?
|
| Myocarditis | 1 | 2012 | 21 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 64 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 217 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 165 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 42 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 229 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 266 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 317 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 7 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1990 | 62 | 0.020 |
Why?
|
| Sepharose | 1 | 1990 | 14 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 445 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 1036 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 200 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2009 | 5 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 2009 | 6 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2009 | 28 | 0.020 |
Why?
|
| Butyrates | 1 | 2009 | 13 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 36 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 18 | 0.020 |
Why?
|
| Quinolines | 1 | 2009 | 25 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 859 | 0.020 |
Why?
|
| Rats | 1 | 1990 | 1554 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 976 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 472 | 0.020 |
Why?
|
| Drug Design | 1 | 2005 | 62 | 0.020 |
Why?
|
| Kinetics | 1 | 2005 | 538 | 0.010 |
Why?
|
| Eosinophil Granule Proteins | 2 | 1995 | 4 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 636 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 2000 | 23 | 0.010 |
Why?
|
| Cinnamates | 1 | 1979 | 6 | 0.010 |
Why?
|
| Adult | 1 | 2007 | 7476 | 0.010 |
Why?
|
| Eosinophil Peroxidase | 1 | 1995 | 1 | 0.010 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 1995 | 2 | 0.010 |
Why?
|
| Complement C4 | 1 | 1995 | 16 | 0.010 |
Why?
|
| Heparin Lyase | 1 | 1993 | 2 | 0.010 |
Why?
|
| Flavobacterium | 1 | 1993 | 2 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1993 | 18 | 0.010 |
Why?
|
| Immunoassay | 1 | 1993 | 35 | 0.010 |
Why?
|
| Complement Factor D | 1 | 1992 | 1 | 0.010 |
Why?
|
| Complement Factor B | 1 | 1992 | 3 | 0.010 |
Why?
|
| Complement Hemolytic Activity Assay | 1 | 1992 | 1 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1992 | 18 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1993 | 506 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1992 | 589 | 0.010 |
Why?
|
| Phenylpyruvic Acids | 1 | 1979 | 1 | 0.000 |
Why?
|
| Phenylacetates | 1 | 1979 | 3 | 0.000 |
Why?
|
| Vanillic Acid | 1 | 1979 | 3 | 0.000 |
Why?
|
| Caffeic Acids | 1 | 1979 | 3 | 0.000 |
Why?
|
| Methods | 1 | 1979 | 27 | 0.000 |
Why?
|
| Phenethylamines | 1 | 1979 | 5 | 0.000 |
Why?
|
| Coumaric Acids | 1 | 1979 | 9 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1979 | 262 | 0.000 |
Why?
|